Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
To investigate the ability of tofacitinib, a Janus kinase (JAK) inhibitor, to treat patients
with cutaneous sarcoidosis and granuloma annulare during 6 months of therapy.